Aim: We compared the waist circumferences (WC) of 1214 diabetics with various parameters in real-life conditions. Patients and Method: The study was carried out by reviewing the anthropometric measurements and biochem...Aim: We compared the waist circumferences (WC) of 1214 diabetics with various parameters in real-life conditions. Patients and Method: The study was carried out by reviewing the anthropometric measurements and biochemical analyzes of diabetics and they were analyzed due to WC status of the patients. Results: Mean total cholesterol level was 204.6 ± 47.1 mg/dL in patients with normal WC and 211.6 ± 45.6 mg/dL in patients with increased WC (p = 0.015). Total cholesterol was found to be a risk factor for WC enlargement (OR: 1.003, 95% CI: 1.001 - 1.006, p = 0.015). HDL-cholesterol appeared to be a risk factor for the increase in WC (OR: 1.005, CI: 1.001 - 1.010, p = 0.029). Median triglyceride level was 158 (41 - 975) mg/dL in the normal WC group, while it was 176 (22 - 1379) mg/dL in the patients with increased WC (p Conclusion: We have demonstrated that the measurement of WC has an important role in diabetes management and is related with inflammatory parameters such as uric acid and GGT.展开更多
AIM: The purpose of this research was to determine the changes of the inflammatory parameters in the long term with the use of dipeptidyl peptidase-4 inhibitors. Material and Methods: In this research we have retrospe...AIM: The purpose of this research was to determine the changes of the inflammatory parameters in the long term with the use of dipeptidyl peptidase-4 inhibitors. Material and Methods: In this research we have retrospectively reviewed the records of 80 patients who had added dipeptidyl peptidase-4 inhibitors (40 sitagliptin and 40 vildagliptin) to their ongoing therapies. Patients’ values of inflammation at the beginning of this process were taken as initial values, while values at the end of this process were considered as final values. Results: A total of 80 patients [38.8% (n = 31) of the patients were male, while 61.3% (n = 49) were female] enrolled in the study. When the whole group was evaluated, the mean age was 56.1 ± 9.7 years. The median follow-up time of the patients with DPP-4 inhibitors was 18 (2 - 64) months. The mean MPV value was measured as 8.79 ± 1.71 fL before DPP-4 inhibitors and it was 10.06 ± 1.42 fL after the follow-up period (p < 0.001). The median value serum GGT was 30.5 (13 - 194) U/L before DPP-4 inhibitor and 29.5 (12 - 112) U/L at the end (p = 0.048). The mean uric acid level before the use of di-peptidyl peptidase-4 inhibitors was 4.7 ± 1.6 mg/dL, and this level was 5.0 ± 1.5 mg/dL after the follow-up period (p = 0.048). Conclusion: In this study, it was observed that MPV and GGT levels were improved by dipeptidyl peptidase-4 inhibitors in long-term.展开更多
文摘Aim: We compared the waist circumferences (WC) of 1214 diabetics with various parameters in real-life conditions. Patients and Method: The study was carried out by reviewing the anthropometric measurements and biochemical analyzes of diabetics and they were analyzed due to WC status of the patients. Results: Mean total cholesterol level was 204.6 ± 47.1 mg/dL in patients with normal WC and 211.6 ± 45.6 mg/dL in patients with increased WC (p = 0.015). Total cholesterol was found to be a risk factor for WC enlargement (OR: 1.003, 95% CI: 1.001 - 1.006, p = 0.015). HDL-cholesterol appeared to be a risk factor for the increase in WC (OR: 1.005, CI: 1.001 - 1.010, p = 0.029). Median triglyceride level was 158 (41 - 975) mg/dL in the normal WC group, while it was 176 (22 - 1379) mg/dL in the patients with increased WC (p Conclusion: We have demonstrated that the measurement of WC has an important role in diabetes management and is related with inflammatory parameters such as uric acid and GGT.
文摘AIM: The purpose of this research was to determine the changes of the inflammatory parameters in the long term with the use of dipeptidyl peptidase-4 inhibitors. Material and Methods: In this research we have retrospectively reviewed the records of 80 patients who had added dipeptidyl peptidase-4 inhibitors (40 sitagliptin and 40 vildagliptin) to their ongoing therapies. Patients’ values of inflammation at the beginning of this process were taken as initial values, while values at the end of this process were considered as final values. Results: A total of 80 patients [38.8% (n = 31) of the patients were male, while 61.3% (n = 49) were female] enrolled in the study. When the whole group was evaluated, the mean age was 56.1 ± 9.7 years. The median follow-up time of the patients with DPP-4 inhibitors was 18 (2 - 64) months. The mean MPV value was measured as 8.79 ± 1.71 fL before DPP-4 inhibitors and it was 10.06 ± 1.42 fL after the follow-up period (p < 0.001). The median value serum GGT was 30.5 (13 - 194) U/L before DPP-4 inhibitor and 29.5 (12 - 112) U/L at the end (p = 0.048). The mean uric acid level before the use of di-peptidyl peptidase-4 inhibitors was 4.7 ± 1.6 mg/dL, and this level was 5.0 ± 1.5 mg/dL after the follow-up period (p = 0.048). Conclusion: In this study, it was observed that MPV and GGT levels were improved by dipeptidyl peptidase-4 inhibitors in long-term.
